PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 215/227	A1	(11) International Publication Number: WO 00/34244
		(43) International Publication Date: 15 June 2000 (15.06.00)

(21) International Application Number: PCT/US99/28428

(22) International Filing Date: 1 December 1999 (01.12.99)

(30) Priority Data:
60/111,079 4 December 1998 (04.12.98) US

(71) Applicant: BRISTOL–MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543–4000 (US).

(72) Inventors: HEWAWASAM, Piyasena; 31 Brookview Lane, Middletown, CT 06457 (US). STARRETT, John, E., Jr.; 23 Hawks Nest Circle, Middletown, CT 06457 (US).

(74) Agent: ALGIERI, Aldo, A.; Bristol–Myers Squibb Company, 5 Research Parkway, P.O. Box 5100, Wallingford, CT 06492–7660 (US).


(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: 3–SUBSTITUTED–4–ARYLQUINOLIN–2–ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS



(I)

(57) Abstract

The present invention provides novel 3–substituted–4–arylquinolin–2–one derivatives having general formula (I) wherein R, R^1, R^2, R^3, R^4, R^5, R^6 and R^7 are as defined herein, or a nontoxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium–activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.